A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Active, not recruiting · Phase 2 · NCT06254950
Conditions: Ulcerative Colitis
At a glance
- Research payments reported, 2025
- $681,961
- U.S. investigators named
- 13
- Sites paid
- 14
- Planned or actual enrollment
- 213
About the trial
- Sponsor
- Takeda
- Tested
- TAK-279 (drug), Placebo (drug)
- Dates
- Started 2024-03-29; completion 2027-08-04
- Results posted
- Not yet
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.
From ClinicalTrials.gov, last updated 2026-08-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $681,961 in research payments for this study in 2025 (158 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John J. Hong, MD Gastroenterology · Fallbrook, CA
- Raymond W. Phillips, M.D. Specialist · Naples, FL
- Lawrence M. Weiss, M.D. Gastroenterology · Clearwater, FL
- Heba N. Iskandar, M.D. Gastroenterology · Atlanta, GA
- Gerald Dryden, MD Gastroenterology · Louisville, KY
- Kenolisa C. Onwueme, M.D., PH.D. Gastroenterology · Baltimore, MD
- Christian D. Stone, MD, MPH Gastroenterology · Las Vegas, NV
- Tauseef Ali, M.D. Gastroenterology · Oklahoma City, OK
- Michelle S. Rosario, M.D. Gastroenterology · Hershey, PA
- Lisa A. Mueller, MD Gastroenterology · Providence, RI
- Matthew R. Barnes, MD Gastroenterology · Greenville, SC
- George A. Duvall, M.D. Gastroenterology · Tyler, TX
- Moazzam M. Sana, D.O. Internal Medicine · Beaumont, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Digestive Disease Consultants PLLC $117,055
- Topography Health Inc $94,022
- Gi Pros Inc $83,222
- Tyler Research Institute LLC $82,393
- Emory University Hospital, GA $60,656
- University of South Florida $48,152
- Novel Research LLC $45,059
- Las Vegas Medical Research LLC $41,590
- West Central Gastroenterology LLP $39,108
- Dz1lfo Multi Global Conglomerate Inc $29,092
- Hightower Clinical LLC $16,475
- United Medical Doctors $11,249
- University of Louisville Research Foundation Inc $5,823
- Gastroenterology Associates PA of Greenville $4,435
- $3,630
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.